Latest Blogs

Jun 25, 2019
As a physician and future pediatric oncologist, Dr. Rachel Offenbacher believes that providers have the responsibility to be vocal about the critical importance of vaccines.
Jun 25, 2019
"We are in a unique moment in terms of the pace of breakthroughs that are being made and the variety of places that breakthroughs are happening," writes Dr. Peter P. Yu.
Jun 25, 2019
We owe it to this vulnerable population to check our assumptions and deliver the highest-quality cancer care in a safe and welcoming environment.
Jun 20, 2019
Key cancer-related topics discussed at the AMA-HOD meeting included alcohol ingestion as a causation risk factor, appropriate guidelines for opioids in the cancer setting, and the use of de-identified patient information.
Subscribe to this column

Matthew S. Katz, MD

Matthew S. Katz, MD, is the Medical Director of Radiation Oncology at Lowell General Hospital and a partner in Radiation Oncology Associates, PA. He is former Chair of the Communications Committee for the American Society for Radiation Oncology (ASTRO) and External Advisory Board member for Mayo Clinic Center for Social Media. He serves on ASCO's Social Media Working Group, ASTRO's Education Committee, and Massachusetts Medical Society's Communications Committee. His areas of prime interest are patient education and health empowerment. Follow Dr. Katz on Twitter @subatomicdoc.

Nov 15, 2018
During my career, pathologists have always been the “doctor’s doctor.” Why can't they be the "patient's doctor" as well?
Dec 06, 2017
Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for their work, and  to implement new findings for our patients.
Jul 12, 2017
Here are 10 reasons why we should look at postoperative radiation for regional melanoma.
Jul 19, 2016
Drug companies play a key role in improving cancer care, but financial toxicity for patients continues to worsen. Eternal vigilance is the price of liberty from excessive drug costs, and we have an ethical obligation to hold pharmaceutical companies accountable.
Apr 08, 2016
We have discussed risk, biology, and the importance of complete reporting. So how do we decide to actually use RNI?
Apr 04, 2016
How we report clinical trials makes interpreting their results harder. Why shouldn’t we all have more information to make better decisions for our patients?

Pages